Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma soars on news of US patent grant

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market”
patents folder
Evgen has patents pending in several other territories across the globe

Shares in Evgen Pharma plc (LON:EVG) soared on Tuesday afternoon after the drug developer revealed it had been granted a US patent which “significantly broadens and extends [its] intellectual property” around its lead product SFX-01.

Shares were up 14% to 25p shortly before the close of play in London.

The new patent covers the manufacturing process of SFX-01 – a synthetic version of the naturally occurring compound sulforaphane – and runs until 2033.

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia,” said chief executive Stephen Franklin.

Under the terms of the licence agreement with PharmAgra Labs Inc – the US lab which invented the compound – Evgen holds the exclusive worldwide rights to the patent.

Evgen is currently conducting two phase II trials of SFX-01; one in advanced breast cancer and the other in a type of stroke called subarachnoid haemorrhage.

Today’s patent grant comes a day after Evgen signed a services agreement with a consortium of Cheshire-based drug development firms.

The group aims to help clients turn promising molecules and compounds into valued medicines, which Evgen hopes to do with SFX-01.

View full EVG profile View Profile

Evgen Pharma Timeline

Article
October 21 2015

Related Articles

blood cells
October 23 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use